scispace - formally typeset
Open AccessJournal ArticleDOI

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

Reads0
Chats0
TLDR
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Abstract
The variable results of positive-negative research with schizophrenics underscore the importance of well-characterized, standardized measurement techniques. We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment. Based on two established psychiatric rating systems, the 30-item PANSS was conceived as an operationalized, drug-sensitive instrument that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. It thus constitutes four scales measuring positive and negative syndromes, their differential, and general severity of illness. Study of 101 schizophrenics found the four scales to be normally distributed and supported their reliability and stability. Positive and negative scores were inversely correlated once their common association with general psychopathology was extracted, suggesting that they represent mutually exclusive constructs. Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Recent advances in the phencyclidine model of schizophrenia.

TL;DR: It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP and the findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia.
Journal ArticleDOI

Practice guideline for the treatment of patients with schizophrenia

Journal ArticleDOI

Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

TL;DR: The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness.
Journal ArticleDOI

The Hierarchical Taxonomy of Psychopathology (HiTOP): A Dimensional Alternative to Traditional Nosologies

TL;DR: The HiTOP promises to improve research and clinical practice by addressing the aforementioned shortcomings of traditional nosologies and provides an effective way to summarize and convey information on risk factors, etiology, pathophysiology, phenomenology, illness course, and treatment response.
References
More filters
Journal ArticleDOI

The Brief Psychiatric Rating Scale

TL;DR: The Brief Psychiatric Rating Scale (BRS) as mentioned in this paper was developed to provide a rapid assessment technique particularly suited to the evaluation of patient change, and it is recommended for use where efficiency, speed, and economy are important considerations.
Journal ArticleDOI

Negative Symptoms in Schizophrenia: Definition and Reliability

TL;DR: The developed Scale for the Assessment of Negative Symptoms has excellent interrater reliability and the five symptom complexes defined by the scale have good internal consistency, which indicates that the conceptual organization of the scale is also cohesive.
Journal ArticleDOI

Negative v positive schizophrenia. Definition and validation.

TL;DR: Criteria for dividing the schizophrenic syndrome into three subtypes was developed: positive, negative, and mixed schizophrenia, and significant differences were noted using external validators such as premorbid adjustment, indices of cognitive dysfunction, ventricular brain ratio, and course in hospital.
Journal ArticleDOI

Molecular pathology of schizophrenia: more than one disease process?

Timothy J. Crow
- 12 Jan 1980 - 
TL;DR: In Florence showed some symptomatic improvement with only minor side effects, but this requires confirmation in a controlled trial, and another approach is based on the finding that suppressor lymphocyte activity is depressed during acute relapses in multiple sclerosis.
Journal ArticleDOI

The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome

TL;DR: The authors describe the Quality of Life Scale (QLS), a 21-item scale based on a semistructured interview designed to assess deficit symptoms and thereby fill an important gap in the range of instruments now available.
Related Papers (5)